SmartLipo365 Issues Voluntary Nationwide Recall of Smart Lipo Due to Undeclared Sibutramine, Desmethylsibutramine and Phenolphthalein

"U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx> · Fri, 18 Dec 2015 13:48:50 -0600

Title:     SmartLipo365 Issues Voluntary Nationwide Recall of Smart Lipo Due to Undeclared Sibutramine, Desmethylsibutramine and Phenolphthalein

  You are subscribed to Recalls, Market Withdrawals and Safety Alerts for U.S. Food & Drug Administration (FDA).
This information has recently been updated and is now available.

SmartLipo365 Issues Voluntary Nationwide Recall of Smart Lipo Due to Undeclared Sibutramine, Desmethylsibutramine and Phenolphthalein
12/18/2015 01:23 PM EST

SmartLipo365 is voluntarily recalling all lots of Smart Lipo (800, 900, 950 mg) capsules, to the consumer level. FDA's analysis found the Smart Lipo products to contain undeclared sibutramine, desmethylsibutramine, and phenolphthalein. Sibutramine is an appetite suppressant that was withdrawn from the U.S. market in October 2010.

For detailed information pertaining to this Recalls, Market Withdrawals and Safety Alerts message, please click the link at the beginning of this bulletin.

Manage your FDA Subscriptions:

Update your preferences or unsubscribe
Questions about this service? Please visit subscriberhelp.govdelivery.com
Other inquiries? webmail@xxxxxxxxxx

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420